AMGN catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 14, 2026Sponsor estimate | NCT06430866Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)Amgen · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | AMGNLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 14, 2026Sponsor estimatePhase 3NCT06430866Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)Amgen · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)Active, not recruitingAMGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 21, 2027Sponsor estimate | NCT06858839Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightAmgen · Obesity | AMGNLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
| Jan 21, 2027Sponsor estimate | NCT06858878Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightAmgen · Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight | AMGNLead | Phase 3 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 21, 2027Sponsor estimatePhase 3NCT06858839Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightAmgen · ObesityActive, not recruitingAMGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 21, 2027Sponsor estimatePhase 3NCT06858878Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightAmgen · Type 2 Diabetes Mellitus (T2DM), Obesity, OverweightActive, not recruitingAMGNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.